Last10K.com

Eagle Pharmaceuticals, Inc. (EGRX) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Eagle Pharmaceuticals, Inc.

CIK: 827871 Ticker: EGRX

Exhibit 99.1

 

 

For Immediate Release

 

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results

 

— Bendeka® market share grew to 92% —

— Bendeka reaches $500 million in cumulative sales in Q1 2017, triggering $25 million milestone —

— 2016 Revenue grew 186% to $189.5 million —

— Q4 2016 income before tax benefit grew to $28.3 million, including $15.6 million of accelerated and non-recurring expenses—

— Q4 2016 EPS grew to $3.75 per basic and $3.52 per diluted share —

— Full Year 2016 income before tax benefit grew to $53.4 million —

— Full Year 2016 EPS grew to $5.24 per basic and $4.96 per diluted share —

— Q4 2016 included $29 million of income tax benefit on release of tax valuation allowance —

 

WOODCLIFF LAKE, N.J.— March 1, 2017—Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2016. Highlights of and subsequent to the fourth quarter of 2016 include:

 

Business Highlights:

 

·                 Bendeka total market share rose to 92%, as of February 24, 2017;

 

·                 Bendeka achieves $500 million in cumulative sales, triggering $25 million sales milestone from Teva in Q1 2017;

 

·                 Eight new patents allowed by the U.S. Patent and Trademark Office for Eagle’s Bendeka portfolio bringing the total to 14 issued or allowed, with 11 issued to-date and ten listed in the Orange Book;

 

·                 The Centers for Medicare & Medicaid Services (CMS) established a unique J-Code (J9034) for Bendeka effective January 1, 2017 triggering a $40 million milestone payment from Teva in Q4 2016;

 

·                 Ryanodex® sales increased to $3.9 million during the fourth quarter;

 

·                 Completed NDA submission for Ryanodex for Exertional Heat Stroke (EHS) and requested Priority Review;

 

·                 NDA for Pemetrexed Injection for non-small cell lung cancer and mesothelioma accepted for filing; PDUFA target date of October 30, 2017;

 

·                 Entered the biologics sector with the acquisition of Arsia Therapeutics, now renamed Eagle Biologics;

 

·                 Board member, David Pernock, joined Eagle management as President and Chief Commercial Officer; and,

 


The following information was filed by Eagle Pharmaceuticals, Inc. (EGRX) on Wednesday, March 1, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Eagle Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eagle Pharmaceuticals, Inc..

Continue

Assess how Eagle Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eagle Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
M & A
Mgmt Change
Other
Filter Subcategory:
All
Expense
Product
Earnings
Shares
Debt
Income
Geography
Cash Flow
Other
Inside Eagle Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Changes In Stockholders' Equity (deficit)
Statements Of Operations
Acquisitions
Acquisitions (tables)
Acquistions - Narrative, Docetaxel (details)
Acquistions - Narrative, Biologics (details)
Acquistions - Schedule Of Assets Acquired And Liabilities Assumed, Biologics (details)
Acquistions - Schedule Of Consideration Transfered, Biologics (details)
Acquistions - Schedule Of Contingent Consideration Fair Value, Docetaxel (details)
Acquistions - Schedule Of Contingent Consideration, Biologic (details)
Acquistions - Schedule Of Pro Forma Information, Biologic (details)
Asset Sales
Asset Sales (details)
Balance Sheet Accounts
Balance Sheet Accounts (tables)
Balance Sheet Accounts - Accrued Expenses (details)
Balance Sheet Accounts - Deferred Revenue (details)
Balance Sheet Accounts - Prepaid And Other Current Assets (details)
Commitments
Commitments (details)
Commitments (tables)
Commitments - Future Minimum Lease Payments (details)
Common Stock And Stock-based Compensation
Common Stock And Stock-based Compensation (tables)
Common Stock And Stock-based Compensation - Fair Value Of Share Options Granted (details)
Common Stock And Stock-based Compensation - Narrative (details)
Common Stock And Stock-based Compensation - Recognized Share-based Compensation (details)
Common Stock And Stock-based Compensation - Schedule Of Common Stock Repurchase (details)
Common Stock And Stock-based Compensation - Share-based Compensation, Options (details)
Income Taxes
Income Taxes - Narrative (details)
Income Taxes (tables)
Income Taxes - Deferred Income Taxes (details)
Income Taxes - Reconciliation (details)
Income Taxes - Schedule Of Income Tax (benefit) Expense (details)
Intangible Assets, Net
Intangible Assets, Net - Schedule Of Intangible Assets (details)
Intangible Assets, Net (tables)
Intangible Assets, Net - Schedule Of Future Amortization Expense (details)
Inventory
Inventory (details)
Inventory (tables)
Legal Proceedings
License Agreements Of Development And Commercialization Rights
License Agreements Of Development And Commercialization Rights (details)
Notes Payable
Notes Payable (details)
Organization And Business Activities
Organization And Business Activities (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Selected Quarterly Financial Data - Unaudited
Selected Quarterly Financial Data - Unaudited (details)
Selected Quarterly Financial Data - Unaudited (tables)
Shares Subject To Redemption ??? Convertible Preferred Stock
Shares Subject To Redemption ??? Convertible Preferred Stock (details)
Subsequent Events
Subsequent Events - Narrative (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Common Shares Equivalents Outstanding (details)
Summary Of Significant Accounting Policies - Earnings Per Share (details)
Summary Of Significant Accounting Policies - Major Customers As A Percentage (details)
Summary Of Significant Accounting Policies - Narrative (details)
Transition Period
Transition Period (details)
Transition Period (tables)
Ticker: EGRX
CIK: 827871
Form Type: 10-K Annual Report
Accession Number: 0000827871-17-000002
Submitted to the SEC: Wed Mar 15 2017 5:22:40 PM EST
Accepted by the SEC: Wed Mar 15 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/egrx/0000827871-17-000002.htm